With more than 20 years of safe, effective use in Europe (backed by decades of postmarketing surveillance data), ERr 731® has been clinically demonstrated, through extensive research, including RCTs, to safely and effectively reduce menopausal symptoms.4 ERr 731® is a therapy designed to alleviate the uncomfortable physical symptoms of menopause, including hot flashes.*1-3
112 perimenopausal women were included in a 12-week randomized clinical trial. (Kaszkin-Bettag, et al. Altern Ther Health Med. 2009)
At 12 weeks, ERr 731® group showed a significant reduction in the number of hot flashes compared to placebo, from a median of 12 to 2—an 83% reduction.* (Figure 1)
The Hot-Flash-Weekly-Weighted-Score (HFWWS) was significantly decreased in ERr 731® group (p<0.0001) but not the placebo group.*
252 peri- and postmenopausal women from 70 gynecological practices were included in a 6-month observational study (Kaszkin-Bettag M, et al. Altern Ther Health Med. 2008)
Subjects showed a significant decrease in Menopause Rating Scale (MRS) total score from a mean of 14.5 points at baseline to 6.5 at 6 months (p<0.0001); all 11 individual symptom scores were improved over baseline.* (Figure 2)
90% of women rated the tolerability of ERr 731® "very good" or "good," and there were no ERr 731®-related AEs